Matt P. Thorpe, M.D., Ph.D.

Open

• Minority-inclusive Imaging Biomarker-based End of Therapy trial for 177Lu-PSMA-617, a randomized de-escalation theranostic trial for metastatic castrate resistant prostate cancer (MI-BET) Rochester, Minn.

  The MI-BET trial is an investigation designed to improve the utilization of 177Lutetium PSMA-617 (177Lu PSMA-617) in metastatic castrate resistant prostate cancer.